Article
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
The Journal of infectious diseases - 15 Jan 2011
Swenson Luke C, Mo Theresa, Dong Winnie W Y, Zhong Xiaoyin, Woods Conan K, Jensen Mark A, Thielen Alexander, Chapman Douglass, Lewis Marilyn, James Ian, Heera Jayvant, Valdez Hernan, Harrigan P Richard
Abstract excerpt
BACKGROUND: The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) studies compared maraviroc versus placebo in treatment-experienced patients with CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1), screened using the original Trofile assay. A subset with non-R5 HIV infection entered the A4001029 trial. We retrospectively examined the performance of a...
Topics
- Anti-HIV Agents
- Clinical Trials as Topic
- Cyclohexanes
- Genotype
- HIV Infections
- HIV-1
- High-Throughput Nucleotide Sequencing
- Humans
- Maraviroc
- RNA, Viral